Journal article
Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers
Abstract
BackgroundThe effect of longer-term use of bone-modifying agent (BMA) on symptomatic skeletal event (SSE) rates in patients with bone metastases remains unclear. This retrospective study of a cohort of patients in a randomized controlled trial evaluated SSEs in patients receiving BMAs at a single cancer center.MethodsData from patients with metastatic breast and castration-resistant prostate cancer (CRPC) were interrogated to evaluate the …
Authors
Alzahrani M; Stober C; Liu M; Awan A; Ng TL; Pond G; Alshamsan B; Vandermeer L; Clemons M
Journal
Supportive Care in Cancer, Vol. 30, No. 5, pp. 3977–3984
Publisher
Springer Nature
Publication Date
May 2022
DOI
10.1007/s00520-021-06714-8
ISSN
0941-4355